Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor‑positive clinical breast cancer

Telang, Nitin T.

doi:10.3892/mmr.2011.617

Cited by 31 publications

(57 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the E 3 : 16α-OHE 1 ratio was increased by about 25 fold in response to treatment with LBF and LBB. These data suggest that EG and CO function predominantly via favoring the formation of anti-proliferative 2-OHE 1 [14,23]. On the other hand, LBB and LBF function via increased formation of 2-OHE 1 as well as via accelerated conversion of the promitogenic16α-OHE 1 to relatively inert E 3 [15].…”

Section: Modulation Of End Point Biomarkers By Herbal Extractsmentioning

confidence: 79%

“…The observed reduction in the number of AI colonies in response to treatment with herbal extracts provides evidence for the efficacy of these extracts towards reduction of breast cancer risk [14,15,23].…”

Section: Model: Mcf-7mentioning

confidence: 93%

“…Non-fractionated herbal extracts were prepared from the bark of Lycium barbarum (LBB) and the fruit of Lycium barbarum (LBF), from the fruit of Cornus officinalis (CO), and from the leaf and stem of Epimedium grandiflorum (EG) according to the published protocol [14,15]. The naturally occurring phyto-chemical Indole-3-Carbinol (I3C, Sigma Chemical Co., St. Louis, MO) was solubilized in DiMethyl Sulfoxide (DMSO).…”

Section: Test Agentsmentioning

confidence: 99%

See 2 more Smart Citations

Cellular Metabolism of Estradiol in Models for Select Molecular Subtypes of Clinical Breast Cancer

Telang¹

2014

J Steroids Hormon Sci

View full text Add to dashboard Cite

The mitogenic ovarian steroid hormone 17β-estradiol (E 2 ) is associated with progression of Estrogen Receptor Positive (ER + ) breast cancer, and ER represents a major therapeutic target for endocrine therapy. In addition to the ER dependent signal transduction, cellular oxidative metabolism of the ER ligand E 2 generates several metabolites with pleotropic growth modulatory effects on breast cancer cells, providing valuable leads for novel therapeutic approach. The molecular classification of clinical breast cancer has defined cancer subtypes based on differential expression of the genes for hormones and growth factor receptors, thereby facilitating subtype targeted therapeutic interventions. However, de novo or acquired resistance to conventional endocrine and targeted small molecule based treatment limits the therapeutic efficacy and promotes therapy resistant disease progression. These aspects emphasize the need for identification of new efficacious non-toxic lead compounds. The present review summarizes critical experiments conducted to i) develop and optimize human tissue derived cell culture models for select molecular subtypes of clinical breast cancer, ii) determine the status of homeostatic growth control, cellular metabolism of 17β-estradiol (E 2 ) and cancer risk in the developed models, and iii) evaluate the therapeutic efficacy and identify possible mechanisms of action of select herbal extracts/phyto-chemical. Additionally, this review discusses the evidence for the role of E 2 metabolism in breast carcinogenesis and therapy. The data generated from the cell culture experiments demonstrate that the models for select molecular sub-types exhibit aberrant hyperproliferation, altered cellular metabolism of E 2 and enhanced cancer risk. Select mechanistically distinct herbal extracts and natural phyto-chemical at their respective maximum cytostatic concentrations modulate cellular metabolism of E 2 favoring generation of anti-proliferative metabolites and inhibit anchorage independent growth, thus reducing cancer risk. Collectively, these data validate the present mechanism based cell culture approach to identify and prioritize novel efficacious lead compounds for subtype targeted therapy of clinical breast cancer.

show abstract

Section: Modulation Of End Point Biomarkers By Herbal Extractsmentioning

confidence: 79%

Section: Model: Mcf-7mentioning

confidence: 93%

Section: Test Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Cellular Metabolism of Estradiol in Models for Select Molecular Subtypes of Clinical Breast Cancer

Telang¹

2014

J Steroids Hormon Sci

View full text Add to dashboard Cite

show abstract

“…These agents, due to their inherently minimal toxicity, may provide testable alternatives for limitations of conventional chemo-endocrine and small molecular-targeted therapeutic options. Previously published data on cell culture models for Luminal A, HER-2 enriched and triple negative molecular subtypes of clinical breast cancer have demonstrated that several mechanistically distinct natural phytochemicals and herbal extracts function as cytostatic and pro-apoptotic agents conferring potent growth inhibitory efficacy in these clinically relevant model systems (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21).…”

Section: Growth Inhibitory Efficacy Of Natural Products In a Model Fomentioning

confidence: 99%

“…Anchorage-independent growth is a sensitive and specific in vitro surrogate endpoint for the tumorigenic potential of carcinoma-derived cell lines (12)(13)(14)(15)(19)(20)(21). For this assay, 184-B5 and MDA-MB-231 cell lines at a predetermined cell density were suspended in 0.33% agar and overlaid on a basement layer of 0.6% agar.…”

Section: Mechanistic Biomarkersmentioning

confidence: 99%

Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer

Telang¹

2017

Biomedical Reports

View full text Add to dashboard Cite

Abstract. Global gene expression profiling identifies predictive and prognostic biomarkers and rationalizes breast cancer subtype-targeted treatment. The Anthracyclin/Taxol and survival pathway specific small molecular inhibitors, constitute current treatment options. These options are associated with acquired tumor resistance and emergence of drug-resistant cancer stem cells. Dietary supplements and constitutive bioactive phytochemicals with relatively low systemic toxicity may provide testable alternatives for current therapy. Human breast epithelial cell lines 184-B5 (non-tumorigenic triple negative cell type) and MDA-MB-231 (breast carcinoma derived triple negative cell type) were used as the experimental models. Putative cancer chemo-preventive natural products and their constitutive bioactive agents represented the test agents. Anchorage independent growth, cell cycle progression and cell apoptosis quantified the treatment efficacy. Compared to the 184-B5 cells, the MDA-MB-231 cells exhibited anchorage-independent growth indicative of persistent cancer risk. Additionally, the MDA-MB-231 cells exhibited hyper-proliferation, accelerated cell cycle progression and inhibited apoptosis indicative of loss of homeostatic growth control. The test agents inhibited anchorage-independent growth via cytostatic and pro-apoptotic effects. The triple negative carcinoma-derived Doxorubicin-resistant phenotype exhibited cancer stem cell markers, including tumor spheroid formation and expression of CD44, NANOG and c-Myc. These data identify clinically relevant mechanistic leads for the efficacy of natural products in the aggressive therapy-resistant breast cancer subtype and suggests a testable approach for cancer stem cell-targeted therapy.

show abstract

Comparative pharmacokinetics of the main compounds of Shanzhuyu extract after oral administration in normal and chronic kidney disease rats

Zhao

Qian

Shang

et al. 2015

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor‑positive clinical breast cancer

Cited by 31 publications

References 33 publications

Cellular Metabolism of Estradiol in Models for Select Molecular Subtypes of Clinical Breast Cancer

Cellular Metabolism of Estradiol in Models for Select Molecular Subtypes of Clinical Breast Cancer

Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer

Comparative pharmacokinetics of the main compounds of Shanzhuyu extract after oral administration in normal and chronic kidney disease rats

Contact Info

Product

Resources

About